Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0906 (Finasteride) in Benign Prostatic Hyperplasia
NCT00127179Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Jan 2004
- Primary completion
- Jul 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing MK0906 (Finasteride) with Placebo (2 arms). Primary endpoint: International Prostate Symptom Score at 48 weeks. Started Jan 2004; status: completed.
02
Drugs
finasteride
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT00127179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00127179.